当前位置: 首页 > 详情页

Long Non-Coding H19 in Lymphocytes: Prognostic Value in Acute Ischemic Stroke Patients

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Capital Med Univ, Xuanwu Hosp, Inst Cerebrovasc Dis Res, Beijing 100053, Peoples R China [2]Capital Med Univ, Xuanwu Hosp, Dept Neurol, Beijing 100053, Peoples R China [3]Beijing Geriatr Med Res Ctr, Beijing Key Lab Translat Med Cerebrovasc Dis, Beijing 100053, Peoples R China
出处:
ISSN:

关键词: AIS lncRNA H19 lymphocytes prognosis

摘要:
Acute ischemic stroke (AIS) is a cerebrovascular disease that seriously affects the physical and mental health and quality of life of patients. However, there is a lack of reliable prognostic prediction methods. The main objective of this study was to investigate the prognostic value of long non-coding RNA (lncRNA) H19 in lymphocytes of patients with AIS, and to construct a prognostic prediction model for AIS including lncRNA H19 in lymphocytes, which would provide new ideas for the prognostic evaluation of AIS. Poor prognosis was defined when the patient's modified Rankin scale (mRS) score at 3 months after AIS onset was greater than 2. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure the level of lncRNA H19 in lymphocytes. Spearman correlation analysis revealed a positive correlation between lncRNA H19 and mRS score at 3 months after AIS onset (r = 0.1977, p = 0.0032), while lncRNA H19 was negatively correlated with white blood cells counts, lymphocytes counts, and neutrophils counts. Logistic regression analysis identified lncRNA H19 as an independent predictor of poor prognosis (OR = 3.062 [1.69-5.548], p < 0.001). Moreover, a nomogram prediction model incorporating lncRNA H19 in lymphocytes demonstrated effective discrimination, calibration, and clinical applicability in predicting AIS outcomes. The findings suggest that lncRNA H19 in lymphocytes could be a valuable prognostic indicator and a potential pharmacological target for AIS patients, and might be a novel pathway for enhanced prognostic evaluation and targeted therapeutic strategies.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 3 区 医学
小类 | 3 区 药物化学 3 区 药学
最新[2023]版:
大类 | 3 区 医学
小类 | 3 区 药物化学 3 区 药学
JCR分区:
出版当年[2022]版:
Q2 CHEMISTRY, MEDICINAL Q2 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY Q2 CHEMISTRY, MEDICINAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者:
第一作者机构: [1]Capital Med Univ, Xuanwu Hosp, Inst Cerebrovasc Dis Res, Beijing 100053, Peoples R China [2]Capital Med Univ, Xuanwu Hosp, Dept Neurol, Beijing 100053, Peoples R China
通讯作者:
通讯机构: [1]Capital Med Univ, Xuanwu Hosp, Inst Cerebrovasc Dis Res, Beijing 100053, Peoples R China [2]Capital Med Univ, Xuanwu Hosp, Dept Neurol, Beijing 100053, Peoples R China [3]Beijing Geriatr Med Res Ctr, Beijing Key Lab Translat Med Cerebrovasc Dis, Beijing 100053, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16461 今日访问量:0 总访问量:871 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院